KR20180086233A - 체크포인트 저해제와 병용되는 2-데옥시-2-플루오로-l-푸코스를 사용하는 암 치료 - Google Patents

체크포인트 저해제와 병용되는 2-데옥시-2-플루오로-l-푸코스를 사용하는 암 치료 Download PDF

Info

Publication number
KR20180086233A
KR20180086233A KR1020187017824A KR20187017824A KR20180086233A KR 20180086233 A KR20180086233 A KR 20180086233A KR 1020187017824 A KR1020187017824 A KR 1020187017824A KR 20187017824 A KR20187017824 A KR 20187017824A KR 20180086233 A KR20180086233 A KR 20180086233A
Authority
KR
South Korea
Prior art keywords
cancer
deoxy
fucose
fluoro
checkpoint inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187017824A
Other languages
English (en)
Korean (ko)
Inventor
쉬라 가르다이
체-렁 로
피터 센터
니콜 오켈리
제시카 필드
Original Assignee
시애틀 지네틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시애틀 지네틱스, 인크. filed Critical 시애틀 지네틱스, 인크.
Publication of KR20180086233A publication Critical patent/KR20180086233A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187017824A 2015-12-04 2016-12-02 체크포인트 저해제와 병용되는 2-데옥시-2-플루오로-l-푸코스를 사용하는 암 치료 Withdrawn KR20180086233A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562263228P 2015-12-04 2015-12-04
US62/263,228 2015-12-04
US201662308583P 2016-03-15 2016-03-15
US62/308,583 2016-03-15
US201662321857P 2016-04-13 2016-04-13
US62/321,857 2016-04-13
PCT/US2016/064783 WO2017096274A1 (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Publications (1)

Publication Number Publication Date
KR20180086233A true KR20180086233A (ko) 2018-07-30

Family

ID=58797961

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187017824A Withdrawn KR20180086233A (ko) 2015-12-04 2016-12-02 체크포인트 저해제와 병용되는 2-데옥시-2-플루오로-l-푸코스를 사용하는 암 치료

Country Status (13)

Country Link
US (1) US20180353524A1 (OSRAM)
EP (1) EP3383404A4 (OSRAM)
JP (1) JP6906520B2 (OSRAM)
KR (1) KR20180086233A (OSRAM)
CN (1) CN108289903B (OSRAM)
AU (1) AU2016362993A1 (OSRAM)
BR (1) BR112018011261A2 (OSRAM)
CA (1) CA3005997A1 (OSRAM)
EA (1) EA201891340A1 (OSRAM)
IL (1) IL259479B (OSRAM)
MX (1) MX385283B (OSRAM)
SG (2) SG11201804263PA (OSRAM)
WO (1) WO2017096274A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019165A2 (en) 2010-08-05 2012-02-09 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
IL271012B2 (en) * 2017-06-07 2023-12-01 Seagen Inc T cells with reduced surface fucosylation and methods for their preparation and use
WO2019075449A1 (en) * 2017-10-13 2019-04-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. FUCOSYLATION AND IMMUNOSURVEILLANCE OF MELANOMA
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
JP2022514299A (ja) * 2018-12-19 2022-02-10 シージェン インコーポレイテッド 抗体の制御されたフコシル化
WO2021034774A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN111973749B (zh) * 2020-09-07 2023-03-21 威海人生药业集团股份有限公司 一种抗肿瘤免疫治疗的药物组合物
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN113274502B (zh) * 2021-05-05 2023-01-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于特定型三阴乳腺癌免疫治疗的组合物
US20240238318A1 (en) * 2021-05-06 2024-07-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. L-fucose and anti-androgen receptor therapy for treatment of cancer
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
CN115466297B (zh) * 2022-08-25 2023-07-07 青岛农业大学 L-岩藻糖的应用以及动物饲料
WO2024077106A2 (en) * 2022-10-04 2024-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Leveraging l-fucose-mediated signaling to induce monocyte-derived dendritic cell polarization
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019165A2 (en) * 2010-08-05 2012-02-09 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물

Also Published As

Publication number Publication date
JP6906520B2 (ja) 2021-07-21
MX2018006674A (es) 2018-11-09
IL259479B (en) 2022-03-01
EA201891340A1 (ru) 2018-11-30
MX385283B (es) 2025-03-18
CN108289903A (zh) 2018-07-17
WO2017096274A1 (en) 2017-06-08
BR112018011261A2 (pt) 2018-11-21
US20180353524A1 (en) 2018-12-13
CA3005997A1 (en) 2017-06-08
SG11201804263PA (en) 2018-06-28
EP3383404A4 (en) 2019-07-31
IL259479A (en) 2018-07-31
JP2019501145A (ja) 2019-01-17
CN108289903B (zh) 2021-08-03
AU2016362993A1 (en) 2018-07-12
SG10202005298RA (en) 2020-07-29
EP3383404A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
JP6906520B2 (ja) チェックポイント阻害剤と組みわせて２−デオキシ−２−フルオロ−ｌ−フコースを用いる癌治療
Sutmuller et al. Synergism of cytotoxic T lymphocyte–associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
EP2893003B1 (en) Selective and controlled expansion of educated nk cells
BR112021002826A2 (pt) construtos de receptor de célula t e usos dos mesmos
AU2015209277B2 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
KR20200133370A (ko) 입양 주입된 t 세포의 지속성 강화 방법
US20250213689A1 (en) Immunogenic composition for the treatment of cancer
US20210060158A1 (en) Agonist of aryl hydrocarbon receptor for use in cancer combination therapy
Provinciali et al. Immunoprevention and immunotherapy of cancer in ageing
JP2022512161A (ja) 免疫療法のための組成物及び方法
WO2019241730A2 (en) Increasing immune activity through modulation of postcellular signaling factors
Watt et al. Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism
Barber et al. NK cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model
US7951374B2 (en) Methods for inhibiting STAT3 signaling in immune cells
CN113316449A (zh) 胍那苄作为免疫疗法的佐剂
JP2021523098A (ja) Ｔ細胞による認識を強化するよう抗原性を調節する方法
EP3630126A1 (en) Ceramide nanoliposomes, compositions and methods of using for immunotherapy
Cycon et al. The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen‐presenting cells
JP2023524435A (ja) Ｔ細胞療法
JP2017526702A (ja) ＰＰＡＲ−γアゴニストを投与する段階を含む、癌を治療する方法
KR20250054790A (ko) 키메라 항원 수용체 도메인
Kojima et al. Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine
EP3750988A1 (en) Improved alpha beta t processed cell production method
Bailey Role of the Akt signalling pathway in CD8 T cell immune response
Paustian et al. Targeting regulatory T cells and other strategies to enable cancer vaccines

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180622

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination